WO2016008011A1 - Functionalised and substituted indoles as anti-cancer agents - Google Patents
Functionalised and substituted indoles as anti-cancer agents Download PDFInfo
- Publication number
- WO2016008011A1 WO2016008011A1 PCT/AU2015/050400 AU2015050400W WO2016008011A1 WO 2016008011 A1 WO2016008011 A1 WO 2016008011A1 AU 2015050400 W AU2015050400 W AU 2015050400W WO 2016008011 A1 WO2016008011 A1 WO 2016008011A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- dimethyl
- carbon atoms
- indol
- ring
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title description 6
- 150000002475 indoles Chemical class 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 271
- 238000000034 method Methods 0.000 claims abstract description 54
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 230000002062 proliferating effect Effects 0.000 claims abstract description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 229910052717 sulfur Inorganic materials 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 208000027866 inflammatory disease Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 125000002009 alkene group Chemical group 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001845 4 membered carbocyclic group Chemical group 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010036774 Proctitis Diseases 0.000 claims description 2
- 206010036783 Proctitis ulcerative Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 208000014793 distal colitis Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 54
- 208000035475 disorder Diseases 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 186
- -1 4- phenethylpiperazin-1 -yl Chemical group 0.000 description 150
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 123
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 94
- 239000000243 solution Substances 0.000 description 78
- 239000011541 reaction mixture Substances 0.000 description 72
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 71
- 229910001868 water Inorganic materials 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 239000007858 starting material Substances 0.000 description 49
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 39
- 238000005481 NMR spectroscopy Methods 0.000 description 38
- 239000012267 brine Substances 0.000 description 38
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 38
- 239000007787 solid Substances 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- 239000012043 crude product Substances 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 35
- 108010085238 Actins Proteins 0.000 description 31
- 102000007469 Actins Human genes 0.000 description 31
- 239000012044 organic layer Substances 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000003818 flash chromatography Methods 0.000 description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 29
- 239000011734 sodium Substances 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- 239000003480 eluent Substances 0.000 description 28
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 27
- 210000003632 microfilament Anatomy 0.000 description 25
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 239000003208 petroleum Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 239000007821 HATU Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 210000004292 cytoskeleton Anatomy 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- HYOAGWAIGJXNQH-UHFFFAOYSA-N 1-bromo-1-chloropropane Chemical compound CCC(Cl)Br HYOAGWAIGJXNQH-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- 206010029260 Neuroblastoma Diseases 0.000 description 8
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 235000009518 sodium iodide Nutrition 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000005937 Tropomyosin Human genes 0.000 description 5
- 108010030743 Tropomyosin Proteins 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- TZEKVGHUGVNMPD-UHFFFAOYSA-N 3-[(2,3-dimethyl-1H-indol-5-yl)methyl]benzoic acid Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC=1C=C(C(=O)O)C=CC=1 TZEKVGHUGVNMPD-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CKDUAQYPFMBHCJ-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-naphthalen-2-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC2=CC=CC=C2C=C1)CCCN1CCN(CC1)C CKDUAQYPFMBHCJ-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- MSMYIZJIJFDENP-UHFFFAOYSA-N methyl 4-[(2,3-dimethyl-1H-indol-5-yl)methyl]benzoate Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C(=O)OC)C=C1 MSMYIZJIJFDENP-UHFFFAOYSA-N 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- MGBNYVZMRJBFKK-UHFFFAOYSA-N (3-nitrophenyl)-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)N2CCN(CCC=3C=CC=CC=3)CC2)=C1 MGBNYVZMRJBFKK-UHFFFAOYSA-N 0.000 description 3
- BOSGCCFPXXTEEN-UHFFFAOYSA-N 1-(2-naphthalen-2-ylethyl)piperazine hydrochloride Chemical compound Cl.C(Cc1ccc2ccccc2c1)N1CCNCC1 BOSGCCFPXXTEEN-UHFFFAOYSA-N 0.000 description 3
- LODHVDKKTUZVDK-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)ethyl]piperazine Chemical compound C1=CC(F)=CC=C1CCN1CCNCC1 LODHVDKKTUZVDK-UHFFFAOYSA-N 0.000 description 3
- WNQDMVUJDKZHEC-UHFFFAOYSA-N 2,3-dimethyl-1h-indol-5-ol Chemical compound C1=C(O)C=C2C(C)=C(C)NC2=C1 WNQDMVUJDKZHEC-UHFFFAOYSA-N 0.000 description 3
- DNJYJMDQLURVBB-UHFFFAOYSA-N 2-(2-bromoethyl)naphthalene Chemical compound C1=CC=CC2=CC(CCBr)=CC=C21 DNJYJMDQLURVBB-UHFFFAOYSA-N 0.000 description 3
- BETRNBJUCZBYAI-UHFFFAOYSA-N 2-quinolin-6-ylethanol Chemical compound N1=CC=CC2=CC(CCO)=CC=C21 BETRNBJUCZBYAI-UHFFFAOYSA-N 0.000 description 3
- LMDKLAWXXCCTAO-UHFFFAOYSA-N 2-quinolin-6-ylethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC=1C=C2C=CC=NC2=CC=1 LMDKLAWXXCCTAO-UHFFFAOYSA-N 0.000 description 3
- ISKPYPPXZFLKJF-UHFFFAOYSA-N 3-[(2,3-dimethyl-1H-indol-5-yl)oxy]benzoic acid Chemical compound CC=1NC2=CC=C(C=C2C=1C)OC=1C=C(C(=O)O)C=CC=1 ISKPYPPXZFLKJF-UHFFFAOYSA-N 0.000 description 3
- DBGZSQZJECIPOY-UHFFFAOYSA-N 4-[(2,3-dimethyl-1H-indol-5-yl)methyl]benzoic acid Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C(=O)O)C=C1 DBGZSQZJECIPOY-UHFFFAOYSA-N 0.000 description 3
- PTIIVQFQQADOHY-UHFFFAOYSA-N 6-(2-piperazin-1-ylethyl)quinoline hydrochloride Chemical compound Cl.C(Cc1ccc2ncccc2c1)N1CCNCC1 PTIIVQFQQADOHY-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- XIPBTCJOZZONKS-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-naphthalen-1-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=CC=C12)CCCN1CCN(CC1)C XIPBTCJOZZONKS-UHFFFAOYSA-N 0.000 description 3
- SODNKPRAQDUOSN-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-naphthalen-2-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC2=CC=CC=C2C=C1)CCCN1CCN(CC1)C SODNKPRAQDUOSN-UHFFFAOYSA-N 0.000 description 3
- 125000005133 alkynyloxy group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- UQCZTYYOUWMXCF-UHFFFAOYSA-N methyl 3-[(2,3-dimethyl-1H-indol-5-yl)methyl]benzoate Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC=1C=C(C(=O)OC)C=CC=1 UQCZTYYOUWMXCF-UHFFFAOYSA-N 0.000 description 3
- HXNSQXXYHWLSKJ-UHFFFAOYSA-N methyl 4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]benzoate Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C(=O)OC)C=C1)CCCN1CCN(CC1)C HXNSQXXYHWLSKJ-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940127084 other anti-cancer agent Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XDLGHQMMAQBEGI-UHFFFAOYSA-N (3-aminophenyl)-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound NC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1 XDLGHQMMAQBEGI-UHFFFAOYSA-N 0.000 description 2
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 2
- PQCXFUXRTRESBD-UHFFFAOYSA-N (4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1 PQCXFUXRTRESBD-UHFFFAOYSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- LKUAPSRIYZLAAO-UHFFFAOYSA-N 1-(2-phenylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=CC=C1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- DSPUJWRECLSVSG-UHFFFAOYSA-N 2,3-dimethyl-1h-indole-5-carbaldehyde Chemical compound C1=C(C=O)C=C2C(C)=C(C)NC2=C1 DSPUJWRECLSVSG-UHFFFAOYSA-N 0.000 description 2
- QZLXBEDMDRAGHA-UHFFFAOYSA-N 2-(6-methoxynaphthalen-2-yl)ethanol Chemical compound C1=C(CCO)C=CC2=CC(OC)=CC=C21 QZLXBEDMDRAGHA-UHFFFAOYSA-N 0.000 description 2
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 2
- VCZANYLMPFRUHG-UHFFFAOYSA-N 2-naphthalen-2-ylethanol Chemical compound C1=CC=CC2=CC(CCO)=CC=C21 VCZANYLMPFRUHG-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NTIMYMCHAZVTII-UHFFFAOYSA-N 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]benzoic acid Chemical compound CC=1NC2=CC=C(C=C2C=1C)OC1=CC=C(C(=O)O)C=C1 NTIMYMCHAZVTII-UHFFFAOYSA-N 0.000 description 2
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 0 CC(C)(C)OC([n]1c(ccc(O)c2)c2c(*)c1*)=O Chemical compound CC(C)(C)OC([n]1c(ccc(O)c2)c2c(*)c1*)=O 0.000 description 2
- RAYLKJCHHYDLHE-UHFFFAOYSA-N CC=1NC2=CC=C(C=C2C=1C)CC1=C(C=CC=C1)C1CN(CCN1CCC1=CC=C(C=C1)F)C=O Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=C(C=CC=C1)C1CN(CCN1CCC1=CC=C(C=C1)F)C=O RAYLKJCHHYDLHE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000007126 N-alkylation reaction Methods 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- YOFVRHBRELCLQR-UHFFFAOYSA-N [3-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F)C)C YOFVRHBRELCLQR-UHFFFAOYSA-N 0.000 description 2
- NHYDRJGCBHMFFM-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-(2-naphthalen-2-ylethyl)piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC2=CC=CC=C2C=C1)C)C NHYDRJGCBHMFFM-UHFFFAOYSA-N 0.000 description 2
- IQJBBMACGUZFNS-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F)CCCCl IQJBBMACGUZFNS-UHFFFAOYSA-N 0.000 description 2
- TWNXWFZZACAUJD-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-quinolin-6-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC=1C=C2C=CC=NC2=CC=1)CCCN1CCN(CC1)C TWNXWFZZACAUJD-UHFFFAOYSA-N 0.000 description 2
- BOUPUEIUTPPLTO-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)CCCN1CCN(CC1)C BOUPUEIUTPPLTO-UHFFFAOYSA-N 0.000 description 2
- UCFFSOKGLBHLHL-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC)CCCN1CCN(CC1)C UCFFSOKGLBHLHL-UHFFFAOYSA-N 0.000 description 2
- FSZMVFFPNUCEJI-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC2=CC=C(C=C2C=C1)OC)CCCN1CCN(CC1)C FSZMVFFPNUCEJI-UHFFFAOYSA-N 0.000 description 2
- NMDDNEOTXIIQMS-UHFFFAOYSA-N [4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]-(4-nitrophenyl)methanone Chemical compound COC=1C=C(C=CC=1)CCN1CCN(CC1)C(=O)C1=CC=C(C=C1)[N+](=O)[O-] NMDDNEOTXIIQMS-UHFFFAOYSA-N 0.000 description 2
- BQNPXKKTWXWQOQ-UHFFFAOYSA-N [4-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-(2-naphthalen-2-ylethyl)piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC2=CC=CC=C2C=C1)C)C BQNPXKKTWXWQOQ-UHFFFAOYSA-N 0.000 description 2
- RBOXWUSNTDMXFO-UHFFFAOYSA-N [4-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1)C)C RBOXWUSNTDMXFO-UHFFFAOYSA-N 0.000 description 2
- KRJNHXVWNQCYFV-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1)CCCN1CCN(CC1)C KRJNHXVWNQCYFV-UHFFFAOYSA-N 0.000 description 2
- ZDPKLZDFVHXRCW-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F)CCCN1CCN(CC1)C ZDPKLZDFVHXRCW-UHFFFAOYSA-N 0.000 description 2
- ZCFQRGNFARPEII-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)CCCN1CCN(CC1)C ZCFQRGNFARPEII-UHFFFAOYSA-N 0.000 description 2
- ZJTMDSCUKACAJQ-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC)CCCN1CCN(CC1)C ZJTMDSCUKACAJQ-UHFFFAOYSA-N 0.000 description 2
- KQUGVBAWURPHHK-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F)CCCN1CCN(CC1)C KQUGVBAWURPHHK-UHFFFAOYSA-N 0.000 description 2
- BFKNVRUEPMTPFJ-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)CCCN1CCN(CC1)C BFKNVRUEPMTPFJ-UHFFFAOYSA-N 0.000 description 2
- RIGXGKLZHLIOEE-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC)CCCN1CCN(CC1)C RIGXGKLZHLIOEE-UHFFFAOYSA-N 0.000 description 2
- KLCNAQIIAGMATI-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC2=CC=C(C=C2C=C1)OC)CCCN1CCN(CC1)C KLCNAQIIAGMATI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- PCUOFKCRVNHDEB-UHFFFAOYSA-N methyl 2-quinolin-6-ylacetate Chemical compound N1=CC=CC2=CC(CC(=O)OC)=CC=C21 PCUOFKCRVNHDEB-UHFFFAOYSA-N 0.000 description 2
- OFWIQFFKRRFDDR-UHFFFAOYSA-N methyl 4-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]benzoate Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC1=CC=C(C(=O)OC)C=C1)C)C OFWIQFFKRRFDDR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005496 tempering Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- DXUKBENXARKCIL-UHFFFAOYSA-N (3-aminophenyl)-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound NC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC DXUKBENXARKCIL-UHFFFAOYSA-N 0.000 description 1
- MHOOQCIXEUJSLZ-UHFFFAOYSA-N (3-aminophenyl)-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound NC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F MHOOQCIXEUJSLZ-UHFFFAOYSA-N 0.000 description 1
- CBTYZEONAFOMKK-UHFFFAOYSA-N (3-aminophenyl)-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound NC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC CBTYZEONAFOMKK-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- PQWVBVBIEAOGBR-UHFFFAOYSA-N (4-aminophenyl)-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F PQWVBVBIEAOGBR-UHFFFAOYSA-N 0.000 description 1
- XEQHJVHRVOBIAS-UHFFFAOYSA-N (4-aminophenyl)-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC XEQHJVHRVOBIAS-UHFFFAOYSA-N 0.000 description 1
- JDIMRRFJMSTNET-UHFFFAOYSA-N (4-aminophenyl)-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound C1=CC(N)=CC=C1C(=O)N1CCN(CCC=2C=CC(F)=CC=2)CC1 JDIMRRFJMSTNET-UHFFFAOYSA-N 0.000 description 1
- ZSPXKICULQCDTJ-UHFFFAOYSA-N (4-aminophenyl)-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC ZSPXKICULQCDTJ-UHFFFAOYSA-N 0.000 description 1
- GEXRRWAMZLAOAC-UHFFFAOYSA-N (4-nitrophenyl)-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN(CCC=2C=CC=CC=2)CC1 GEXRRWAMZLAOAC-UHFFFAOYSA-N 0.000 description 1
- PHJFLPMVEFKEPL-UHFFFAOYSA-N (6-methoxy-2-naphthyl)acetic acid Chemical compound C1=C(CC(O)=O)C=CC2=CC(OC)=CC=C21 PHJFLPMVEFKEPL-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- QKQWSZQBIZXBOC-UHFFFAOYSA-N 1-(2-bromoethyl)-7-methoxynaphthalene Chemical compound C1=CC=C(CCBr)C2=CC(OC)=CC=C21 QKQWSZQBIZXBOC-UHFFFAOYSA-N 0.000 description 1
- GPHCPUFIWQJZOI-UHFFFAOYSA-N 1-(2-bromoethyl)naphthalene Chemical compound C1=CC=C2C(CCBr)=CC=CC2=C1 GPHCPUFIWQJZOI-UHFFFAOYSA-N 0.000 description 1
- SOQVIKQGSDMYCX-UHFFFAOYSA-N 1-(2-naphthalen-1-ylethyl)piperazine hydrochloride Chemical compound Cl.C(Cc1cccc2ccccc12)N1CCNCC1 SOQVIKQGSDMYCX-UHFFFAOYSA-N 0.000 description 1
- MXNHEKIHSVXJPG-UHFFFAOYSA-N 1-(2-naphthalen-2-ylethyl)piperazine Chemical compound C=1C=C2C=CC=CC2=CC=1CCN1CCNCC1 MXNHEKIHSVXJPG-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- JNRYEINHOYYNMG-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)ethyl]piperazine Chemical compound COC1=CC=CC(CCN2CCNCC2)=C1 JNRYEINHOYYNMG-UHFFFAOYSA-N 0.000 description 1
- RYZSHSUNYMOYIP-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)ethyl]piperazine hydrochloride Chemical compound Cl.COc1cccc(CCN2CCNCC2)c1 RYZSHSUNYMOYIP-UHFFFAOYSA-N 0.000 description 1
- NRFWUUMBJDJBGP-UHFFFAOYSA-N 1-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazine hydrochloride Chemical compound Cl.COc1ccc2cc(CCN3CCNCC3)ccc2c1 NRFWUUMBJDJBGP-UHFFFAOYSA-N 0.000 description 1
- FRVXUVJOYTYBOW-UHFFFAOYSA-N 1-[2-(7-methoxynaphthalen-1-yl)ethyl]piperazine hydrochloride Chemical compound Cl.COc1ccc2cccc(CCN3CCNCC3)c2c1 FRVXUVJOYTYBOW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- HSKBGALULOFBAM-UHFFFAOYSA-N 2,3-dihydroxy-4-methylidene-3h-naphthalene-1-carboxylic acid Chemical class C1=CC=C2C(=C)C(O)C(O)=C(C(O)=O)C2=C1 HSKBGALULOFBAM-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- WNLPAQFDNAVWLM-UHFFFAOYSA-N 2-(2-bromoethyl)-6-methoxynaphthalene Chemical compound C1=C(CCBr)C=CC2=CC(OC)=CC=C21 WNLPAQFDNAVWLM-UHFFFAOYSA-N 0.000 description 1
- VDIFLYQCJAFOLQ-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)ethanol Chemical compound C1=CC=C(CCO)C2=CC(OC)=CC=C21 VDIFLYQCJAFOLQ-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- RXWNCMHRJCOWDK-UHFFFAOYSA-N 2-naphthalen-1-ylethanol Chemical compound C1=CC=C2C(CCO)=CC=CC2=C1 RXWNCMHRJCOWDK-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CFVILHFXMRQYSG-UHFFFAOYSA-N 2-quinolin-6-ylacetic acid Chemical compound N1=CC=CC2=CC(CC(=O)O)=CC=C21 CFVILHFXMRQYSG-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- RFSXOTXHWAXUIB-UHFFFAOYSA-N 3-[2-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-4-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazine-1-carbaldehyde Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=C(C=CC=C1)C1CN(CCN1CCC1=CC2=CC=C(C=C2C=C1)OC)C=O RFSXOTXHWAXUIB-UHFFFAOYSA-N 0.000 description 1
- DQWACHUXXUEHNT-UHFFFAOYSA-N 3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]benzoic acid Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C(=O)O)C=CC=1)CCCN1CCN(CC1)C DQWACHUXXUEHNT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- MDHIEUCEDBMLFE-UHFFFAOYSA-N 4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]benzoic acid Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C(=O)O)C=C1)CCCN1CCN(CC1)C MDHIEUCEDBMLFE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OMOXZTXJSWQNKN-UHFFFAOYSA-N 5-bromo-1-(3-chloropropyl)-2,3-dimethylindole Chemical compound BrC=1C=C2C(=C(N(C2=CC=1)CCCCl)C)C OMOXZTXJSWQNKN-UHFFFAOYSA-N 0.000 description 1
- FUGUBHVTDFUZBY-UHFFFAOYSA-N 5-bromo-2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indole Chemical compound BrC=1C=C2C(=C(N(C2=CC=1)CCCN1CCN(CC1)C)C)C FUGUBHVTDFUZBY-UHFFFAOYSA-N 0.000 description 1
- IOGAIEWEHFPGNO-UHFFFAOYSA-N 5-bromo-2,3-dimethyl-1h-indole Chemical compound C1=C(Br)C=C2C(C)=C(C)NC2=C1 IOGAIEWEHFPGNO-UHFFFAOYSA-N 0.000 description 1
- GZSTUEGIANKNTE-UHFFFAOYSA-N 5-methoxy-2,3-dimethyl-1h-indole Chemical compound COC1=CC=C2NC(C)=C(C)C2=C1 GZSTUEGIANKNTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WOBFGOFPSOQUQH-OBYFIISYSA-N C/C=C(\C=C(/C)\Cc1ccc2[n](CCCN3CCN(C)CC3)c(C)c(C)c2c1)/C(N1CCN(CCc2ccc(cccc3)c3c2)CC1)=O Chemical compound C/C=C(\C=C(/C)\Cc1ccc2[n](CCCN3CCN(C)CC3)c(C)c(C)c2c1)/C(N1CCN(CCc2ccc(cccc3)c3c2)CC1)=O WOBFGOFPSOQUQH-OBYFIISYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KYYCTRJDLTXKGX-UHFFFAOYSA-N Cc(c1c2)c(C)[n](CCCN3CCN(C)CC3)c1ccc2Nc1cccc(C(N2CCN(CCc(cc3)ccc3F)CC2)=O)c1 Chemical compound Cc(c1c2)c(C)[n](CCCN3CCN(C)CC3)c1ccc2Nc1cccc(C(N2CCN(CCc(cc3)ccc3F)CC2)=O)c1 KYYCTRJDLTXKGX-UHFFFAOYSA-N 0.000 description 1
- ABNUJTVPUMOXTK-UHFFFAOYSA-N Cc(c1c2)c(C)[n](CCCN3CCN(C)CC3)c1ccc2Nc1cccc(C(N2CCN(CCc(cc3)ccc3OC)CC2)=O)c1 Chemical compound Cc(c1c2)c(C)[n](CCCN3CCN(C)CC3)c1ccc2Nc1cccc(C(N2CCN(CCc(cc3)ccc3OC)CC2)=O)c1 ABNUJTVPUMOXTK-UHFFFAOYSA-N 0.000 description 1
- VJKJXULDBQMOHK-UHFFFAOYSA-N Cc(c1c2)c(C)[n](CCCN3CCN(C)CC3)c1ccc2Oc1cccc(C(N2CCN(CCc3ccccc3)CC2)=O)c1 Chemical compound Cc(c1c2)c(C)[n](CCCN3CCN(C)CC3)c1ccc2Oc1cccc(C(N2CCN(CCc3ccccc3)CC2)=O)c1 VJKJXULDBQMOHK-UHFFFAOYSA-N 0.000 description 1
- IIFKFGNSUAMMPQ-UHFFFAOYSA-N Cc1c(C)[n](CCCN2CCNCC2)c(cc2)c1cc2Nc1cccc(C(N2CCN(CCc3ccc4OCOc4c3)CC2)=O)c1 Chemical compound Cc1c(C)[n](CCCN2CCNCC2)c(cc2)c1cc2Nc1cccc(C(N2CCN(CCc3ccc4OCOc4c3)CC2)=O)c1 IIFKFGNSUAMMPQ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CVEUODZPTLNNPU-UHFFFAOYSA-N [3-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-(2-naphthalen-2-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC2=CC=CC=C2C=C1 CVEUODZPTLNNPU-UHFFFAOYSA-N 0.000 description 1
- ZPAUUOYNRNAIOE-UHFFFAOYSA-N [3-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC2=CC=C(C=C2C=C1)OC ZPAUUOYNRNAIOE-UHFFFAOYSA-N 0.000 description 1
- ZCUBYUIFOSFXJW-UHFFFAOYSA-N [3-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-[2-(7-methoxynaphthalen-1-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=C(C=C12)OC ZCUBYUIFOSFXJW-UHFFFAOYSA-N 0.000 description 1
- WWPNMOVWLZKNIX-UHFFFAOYSA-N [3-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F)C)C WWPNMOVWLZKNIX-UHFFFAOYSA-N 0.000 description 1
- ZPTDCLTZOIRHIW-UHFFFAOYSA-N [3-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)C)C ZPTDCLTZOIRHIW-UHFFFAOYSA-N 0.000 description 1
- FUKFJRUEOJOGOF-UHFFFAOYSA-N [3-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC)C)C FUKFJRUEOJOGOF-UHFFFAOYSA-N 0.000 description 1
- FNEHSJQRIWHZKS-UHFFFAOYSA-N [3-[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]oxyphenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)OC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F)CCCN1CCN(CC1)C FNEHSJQRIWHZKS-UHFFFAOYSA-N 0.000 description 1
- QIYFRKRZYMIKAW-UHFFFAOYSA-N [3-[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]oxyphenyl]-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)OC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC)CCCN1CCN(CC1)C QIYFRKRZYMIKAW-UHFFFAOYSA-N 0.000 description 1
- LGMPOFDGMRHXCB-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-(2-naphthalen-1-ylethyl)piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=CC=C12)C)C LGMPOFDGMRHXCB-UHFFFAOYSA-N 0.000 description 1
- GODADUGZGJSLBF-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1)CCCCl GODADUGZGJSLBF-UHFFFAOYSA-N 0.000 description 1
- UOETVKADPGOPFH-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F)CCCCl UOETVKADPGOPFH-UHFFFAOYSA-N 0.000 description 1
- YHOISWXYEVKUSA-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)CCCCl YHOISWXYEVKUSA-UHFFFAOYSA-N 0.000 description 1
- OJLNTBNXXIIGJQ-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC)CCCCl OJLNTBNXXIIGJQ-UHFFFAOYSA-N 0.000 description 1
- YUUUTXJKLFJWHH-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC2=CC=C(C=C2C=C1)OC)C)C YUUUTXJKLFJWHH-UHFFFAOYSA-N 0.000 description 1
- NFKGIPUNZVDTQE-UHFFFAOYSA-N [3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(7-methoxynaphthalen-1-yl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=C(C=C12)OC)C)C NFKGIPUNZVDTQE-UHFFFAOYSA-N 0.000 description 1
- LRLCTQFPFTWPBX-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1)CCCN1CCN(CC1)C LRLCTQFPFTWPBX-UHFFFAOYSA-N 0.000 description 1
- JWXQRYRCECNYMC-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F)CCCN1CCN(CC1)C JWXQRYRCECNYMC-UHFFFAOYSA-N 0.000 description 1
- OQJZAUVVTBKVBM-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)CCCN1CCN(CC1)C OQJZAUVVTBKVBM-UHFFFAOYSA-N 0.000 description 1
- DYKNINZTCHFMMP-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1)CCCN1CCN(CC1)C DYKNINZTCHFMMP-UHFFFAOYSA-N 0.000 description 1
- GLUAULNPGQVDFQ-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-quinolin-7-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C2C=CC=NC2=C1)CCCN1CCN(CC1)C GLUAULNPGQVDFQ-UHFFFAOYSA-N 0.000 description 1
- RXBDUMZYLICBME-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F)CCCN1CCN(CC1)C RXBDUMZYLICBME-UHFFFAOYSA-N 0.000 description 1
- TWLSLOFKPWHBCT-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F)CCCN1CCN(CC1)C TWLSLOFKPWHBCT-UHFFFAOYSA-N 0.000 description 1
- HTBLGYIEAWWSTP-UHFFFAOYSA-N [3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(7-methoxynaphthalen-1-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C=CC=1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=C(C=C12)OC)CCCN1CCN(CC1)C HTBLGYIEAWWSTP-UHFFFAOYSA-N 0.000 description 1
- WVJIYZATJHLUGA-UHFFFAOYSA-N [4-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-(2-naphthalen-1-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=CC=C12 WVJIYZATJHLUGA-UHFFFAOYSA-N 0.000 description 1
- RYGGFJNEKGNOME-UHFFFAOYSA-N [4-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-(2-naphthalen-2-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC2=CC=CC=C2C=C1 RYGGFJNEKGNOME-UHFFFAOYSA-N 0.000 description 1
- REBYJAWJHJJEOU-UHFFFAOYSA-N [4-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1 REBYJAWJHJJEOU-UHFFFAOYSA-N 0.000 description 1
- CHOODTSLOLTMRQ-UHFFFAOYSA-N [4-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC CHOODTSLOLTMRQ-UHFFFAOYSA-N 0.000 description 1
- BFAYXLAYHBAVBZ-UHFFFAOYSA-N [4-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC2=CC=C(C=C2C=C1)OC BFAYXLAYHBAVBZ-UHFFFAOYSA-N 0.000 description 1
- JMVLJWRUGYMZKI-UHFFFAOYSA-N [4-[(2,3-dimethyl-1H-indol-5-yl)methyl]phenyl]-[4-[2-(7-methoxynaphthalen-1-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1NC2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=C(C=C12)OC JMVLJWRUGYMZKI-UHFFFAOYSA-N 0.000 description 1
- FKPJJDWDZFNSOB-UHFFFAOYSA-N [4-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1)C)C FKPJJDWDZFNSOB-UHFFFAOYSA-N 0.000 description 1
- SORCGDAERLRGTH-UHFFFAOYSA-N [4-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)F)C)C SORCGDAERLRGTH-UHFFFAOYSA-N 0.000 description 1
- PNXJCOHNEMMYAF-UHFFFAOYSA-N [4-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)C)C PNXJCOHNEMMYAF-UHFFFAOYSA-N 0.000 description 1
- VLLDNNCUMHUGTC-UHFFFAOYSA-N [4-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F)C)C VLLDNNCUMHUGTC-UHFFFAOYSA-N 0.000 description 1
- BALCULZDVICBMX-UHFFFAOYSA-N [4-[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]oxyphenyl]-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)OC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)OC)C)C BALCULZDVICBMX-UHFFFAOYSA-N 0.000 description 1
- CHQDTGGXXSQGTJ-UHFFFAOYSA-N [4-[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]oxyphenyl]-[4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)OC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC(=CC=C1)OC)CCCN1CCN(CC1)C CHQDTGGXXSQGTJ-UHFFFAOYSA-N 0.000 description 1
- QDYNLGRSXFDRSI-UHFFFAOYSA-N [4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]-(3-nitrophenyl)methanone Chemical compound FC=1C=C(CCN2CCN(CC2)C(=O)C2=CC(=CC=C2)[N+](=O)[O-])C=CC=1 QDYNLGRSXFDRSI-UHFFFAOYSA-N 0.000 description 1
- GKLLYERECUJPAX-UHFFFAOYSA-N [4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]-(4-nitrophenyl)methanone Chemical compound FC=1C=C(CCN2CCN(CC2)C(=O)C2=CC=C(C=C2)[N+](=O)[O-])C=CC=1 GKLLYERECUJPAX-UHFFFAOYSA-N 0.000 description 1
- SOEOEZNRWITBAZ-UHFFFAOYSA-N [4-[2-(3-methoxyphenyl)ethyl]piperazin-1-yl]-(3-nitrophenyl)methanone Chemical compound COC=1C=C(C=CC=1)CCN1CCN(CC1)C(=O)C1=CC(=CC=C1)[N+](=O)[O-] SOEOEZNRWITBAZ-UHFFFAOYSA-N 0.000 description 1
- FOFADXCSZQFNMP-UHFFFAOYSA-N [4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-(3-nitrophenyl)methanone Chemical compound FC1=CC=C(CCN2CCN(CC2)C(=O)C2=CC(=CC=C2)[N+](=O)[O-])C=C1 FOFADXCSZQFNMP-UHFFFAOYSA-N 0.000 description 1
- GCDKXBXVZANBTN-UHFFFAOYSA-N [4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-(4-nitrophenyl)methanone Chemical compound FC1=CC=C(CCN2CCN(CC2)C(=O)C2=CC=C(C=C2)[N+](=O)[O-])C=C1 GCDKXBXVZANBTN-UHFFFAOYSA-N 0.000 description 1
- KVOCBWACTLFLRX-UHFFFAOYSA-N [4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-(3-nitrophenyl)methanone Chemical compound COC1=CC=C(C=C1)CCN1CCN(CC1)C(=O)C1=CC(=CC=C1)[N+](=O)[O-] KVOCBWACTLFLRX-UHFFFAOYSA-N 0.000 description 1
- HNEXUDAXTNVWRT-UHFFFAOYSA-N [4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]-(4-nitrophenyl)methanone Chemical compound COC1=CC=C(C=C1)CCN1CCN(CC1)C(=O)C1=CC=C(C=C1)[N+](=O)[O-] HNEXUDAXTNVWRT-UHFFFAOYSA-N 0.000 description 1
- ZWDBUONRUKGECN-UHFFFAOYSA-N [4-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-(2-naphthalen-1-ylethyl)piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=CC=C12)C)C ZWDBUONRUKGECN-UHFFFAOYSA-N 0.000 description 1
- SUKJFECSVFDAKH-UHFFFAOYSA-N [4-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(6-methoxynaphthalen-2-yl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC2=CC=C(C=C2C=C1)OC)C)C SUKJFECSVFDAKH-UHFFFAOYSA-N 0.000 description 1
- MLCGKXDIYRSNJU-UHFFFAOYSA-N [4-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]phenyl]-[4-[2-(7-methoxynaphthalen-1-yl)ethyl]piperazin-1-yl]methanone Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=C(C=C12)OC)C)C MLCGKXDIYRSNJU-UHFFFAOYSA-N 0.000 description 1
- GOGIPQFAOSGNCU-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]amino]phenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)NC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F)CCCN1CCN(CC1)C GOGIPQFAOSGNCU-UHFFFAOYSA-N 0.000 description 1
- UHJZBBKUSYIHTO-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-naphthalen-1-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=CC=C12)CCCN1CCN(CC1)C UHJZBBKUSYIHTO-UHFFFAOYSA-N 0.000 description 1
- YYJZQHGQKYYWHD-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC=C1)CCCN1CCN(CC1)C YYJZQHGQKYYWHD-UHFFFAOYSA-N 0.000 description 1
- LPDRRWYEIFCNTI-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-quinolin-6-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC=1C=C2C=CC=NC2=CC=1)CCCN1CCN(CC1)C LPDRRWYEIFCNTI-UHFFFAOYSA-N 0.000 description 1
- YKRPQGHZLXEBOD-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-(2-quinolin-7-ylethyl)piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C2C=CC=NC2=C1)CCCN1CCN(CC1)C YKRPQGHZLXEBOD-UHFFFAOYSA-N 0.000 description 1
- QOVXESSNZWADBC-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=C(C=C1)F)CCCN1CCN(CC1)C QOVXESSNZWADBC-UHFFFAOYSA-N 0.000 description 1
- MSAJFBPLCRHHMZ-UHFFFAOYSA-N [4-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]phenyl]-[4-[2-(7-methoxynaphthalen-1-yl)ethyl]piperazin-1-yl]methanone Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC1=CC=C(C=C1)C(=O)N1CCN(CC1)CCC1=CC=CC2=CC=C(C=C12)OC)CCCN1CCN(CC1)C MSAJFBPLCRHHMZ-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- CYKIHIBNSFRKQP-UHFFFAOYSA-N benzo[f][1]benzothiole Chemical compound C1=CC=C2C=C(SC=C3)C3=CC2=C1 CYKIHIBNSFRKQP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- FILFNBKSVOHNPK-UHFFFAOYSA-N methyl 3-[[1-(3-chloropropyl)-2,3-dimethylindol-5-yl]methyl]benzoate Chemical compound ClCCCN1C(=C(C2=CC(=CC=C12)CC=1C=C(C(=O)OC)C=CC=1)C)C FILFNBKSVOHNPK-UHFFFAOYSA-N 0.000 description 1
- HYFJDBWPIAFVSM-UHFFFAOYSA-N methyl 3-[[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]methyl]benzoate Chemical compound CC=1N(C2=CC=C(C=C2C=1C)CC=1C=C(C(=O)OC)C=CC=1)CCCN1CCN(CC1)C HYFJDBWPIAFVSM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- BDAVKZOFQZJHAL-UHFFFAOYSA-N tert-butyl 4-(2-naphthalen-2-ylethyl)piperazine-1-carboxylate Chemical compound C1=C(C=CC2=CC=CC=C12)CCN1CCN(CC1)C(=O)OC(C)(C)C BDAVKZOFQZJHAL-UHFFFAOYSA-N 0.000 description 1
- NBSOPEUQBCSWBT-UHFFFAOYSA-N tert-butyl 4-(2-quinolin-6-ylethyl)piperazine-1-carboxylate Chemical compound N1=CC=CC2=CC(=CC=C12)CCN1CCN(CC1)C(=O)OC(C)(C)C NBSOPEUQBCSWBT-UHFFFAOYSA-N 0.000 description 1
- IRDQLJZPVQWDPO-UHFFFAOYSA-N tert-butyl 5-(3-methoxycarbonylphenoxy)-2,3-dimethylindole-1-carboxylate Chemical compound COC(=O)C=1C=C(OC=2C=C3C(=C(N(C3=CC=2)C(=O)OC(C)(C)C)C)C)C=CC=1 IRDQLJZPVQWDPO-UHFFFAOYSA-N 0.000 description 1
- DVEDLIWSBULLFT-UHFFFAOYSA-N tert-butyl 5-(4-methoxycarbonylphenoxy)-2,3-dimethylindole-1-carboxylate Chemical compound COC(=O)C1=CC=C(OC=2C=C3C(=C(N(C3=CC=2)C(=O)OC(C)(C)C)C)C)C=C1 DVEDLIWSBULLFT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates broadly to pharmaceutical agents as treatments for proliferative disease such as cancer and a range of degenerative diseases such as osteoarthritis, atherosclerosis, heart disease and inflammatory bowel disease.
- the present invention relates to pharmaceutical agents which comprise aryl and/or alkyl substituted indole compounds.
- the invention further relates to methods for treating or preventing a disease or disorder, such as a proliferative disorder (preferably cancer).
- a proliferative disorder preferably cancer
- the invention also relates to processes for preparing the compounds. Background of the invention
- a potential new method of specifically attacking cancer cells is through disruption of cancer cells' cellular skeletal system comprised predominantly of actin.
- actin cytoskeleton is intimately involved in cell division and cell migration.
- actin plays a ubiquitous role as the cytoskeleton of tumour cells and the actin filaments of the muscle sarcomere.
- the differing roles but similarity in structure make actin a hard target for drug development, due to unwanted off-target side effects.
- the invention seeks to address one or more of the above mentioned problems, and/or to provide improvements in therapy (e.g. cancer therapy) and in one embodiment provides an anti-tropomyosin compound.
- therapy e.g. cancer therapy
- an anti-tropomyosin compound in one aspect of the invention there is provided a compound of general formula (I), or a pharmaceutically acceptable drug or prodrug thereof:
- Ri and R 2 are independently H or C1-C6 alkyl
- R 3 is N(R 7 ) 2 or a 3- to 7-membered carbocyclic ring wherein between 1 and 3 ring carbon atoms may optionally be replaced by S, N, 0, NH or NR 7 and wherein the ring may optionally be substituted by R 7 ;
- R 4 and R 5 are independently or a 5- or 6-membered carbocyclic ring wherein between 1 and 3 ring carbon atoms may optionally be replaced with S, N, O, NH or NR 8 and wherein the ring may optionally be substituted by R 8 ;
- R6 is a C1 -C6 alkyl group, a C2-C6 alkene group or a monocyclic or bicyclic carbocyclic ring having between 5 and 10 ring carbon atoms wherein 1 or 2 ring carbon atoms may optionally be replaced with S, O, N, NH or NR 7 and wherein the ring may optionally be substituted with R 8 , or R 6 is
- Xi is absent or is an alkyl group having between 1 and 10 carbon atoms, or an alkenyl group having between 2 and 10 carbon atoms;
- X 2 , X3 and X 4 are independently absent or selected from the group consisting of: S, O, NH, NHR 7 , C(O), C(0)NH, an alkyl group having between 1 and 10 carbon atoms, an alkene group having between 2 and 10 carbon atoms, CH(R 7 )CHC(R 7 )C(0), (CH 2 )o-5C(R 7 )C(R 7 )(CH 2 )o-5, and a 5- or 6- membered carbocyclic ring wherein between 1 and 3 ring carbon atoms may optionally be replaced by S, N, O, NH or NR 7 ;
- X 5 is O, NH, NR 7 or S;
- R 7 is H, Ci-C 6 alkyl, (CH 2 )i-50Me, CF 3 , CN or OCF 3 ;
- Rs is H, OH, alkyl (e.g. C1-C6 alkyl), alkenyl (e.g. C2-C6 alkenyl), halo, alkoxy, amino, alkylamino, dialkylamino or a dioxolane ring fused to 2 adjacent carbon atoms of R 4 , R 5 or R 6 .
- Xi may be an alkyl group having between 1 and 10 carbon atoms (e.g. between 1 and 5 carbon atoms).
- R 3 may be N(R 7 ) 2 or a 4-, 5-, 6- or 7-membered carbocyclic ring (e.g. cycloalkyl) wherein between 1 and 3 ring carbon atoms may optionally be replaced by S, N, O, NH or NR 7 and wherein the ring may optionally be substituted by R 7 .
- Ri and R 2 may be independently C1-C6 alkyl (e.g. Ri may be, for example, CH 3 or CH 2 CH 3 and R 2 may be, for example, CH 3 or CH 2 CH 3 ).
- X 2 , X 3 and X 4 may be independently selected from the group consisting of: S, O, NH, NHR 7 , C(O), C(O)NH, an alkyl group having between 1 and 10 carbon atoms (e.g. between 1 and 5 carbon atoms), CH(R 7 )CHC(R 7 )C(O), (CH 2 ) 0- 5C(R 7 )C(R 7 )(CH 2 ) 0- 5, and a 5-membered carbocyclic ring (e.g. aryl) wherein between 1 and 3 ring carbon atoms (e.g. 1 or 2 ring carbon atoms) may optionally be replaced by S, N, O, NH or NR 7 (e.g. N and/or O).
- R 4 and R 5 may be independently a 5- or 6-membered aryl or cycloalkyl group wherein between 1 and 3 ring carbon atoms may optionally be replaced with S, N, O, NH or NR 8 and wherein the ring may optionally be substituted by R 8 .
- R 6 may be a C1-C6 alkyl group (e.g. CH 3 or CH 2 CH 3 ) or a monocyclic or bicyclic aryl group having between 6 and 10 ring carbon atoms wherein 1 or 2 ring carbon atoms may optionally be replaced with S, O, N, NH or NR 7 and wherein the ring may optionally be substituted with R 8 .
- R6 may be:
- the compound of formula (I), or a pharmaceutically acceptable drug or prodrug thereof is:
- Ri and R 2 may both be CH 3 or CH 2 CH 3 .
- Xi may be an alkyl group having between 1 and 5 carbon atoms (e.g. CH 2 , (CH 2 )2 or (CH 2 ) 3 ).
- R 3 may be a 4-, 5-, 6- or 7-membered cycloalkyi group wherein between 1 and 3 ring carbon atoms may optionally be replaced by S, N, O, NH or NR 7 and wherein the ring may optionally be substituted by R 7 , such as:
- R 3 may be a 6-membered cycloalkyi group wherein between 1 and 3 ring carbon atoms may optionally be replaced by S, N, O, NH or NR 7 and wherein the ring may optionally be substituted by R 7 , such as:
- X 5 may be NH or NR 7 .
- R 7 may be Ci-C 6 alkyl (e.g. CH 3 or CH 2 CH 3 ).
- X 2 may be an alkyl group having between 1 and 10 carbon atoms, O or NH.
- X 2 may be (CH 2 )i-5 (e.g. CH 2 , (CH 2 ) 2 or (CH 2 ) 3 ).
- R 4 may be a 5- or 6-membered aryl group wherein between 1 and 3 ring carbon atoms may optionally be replaced with S, N, O, NH or NR 8 and wherein the ring may optionally be substituted by R 8 , such as:
- R 8 may be H.
- X 3 may be C(O).
- R 5 may be a 5- or 6-membered cycloalkyl group wherein between 1 and 3 ring carbon atoms may optionally be replaced with S, N, O, NH or NR 8 and wherein the ring may optionally be substituted by R 8 , such as:
- X 4 may be an alkyl group having between 1 and 5 carbon atoms (e.g. CH 2 , (CH 2 ) 2 or
- R 6 may be a bicyclic aryl group having 9 or 10 ring carbon atoms wherein 1 or 2 ring carbon atoms may optionally be replaced with S, O, N, NH or NR 7 and wherein the ring may optionally be substituted with R 8 .
- R 6 may be selected from:
- R 8 may be selected from H, alkoxy, halo and a dioxalane ring fused to two adjacent carbon atoms of R 6 .
- Rs may be alkoxy (e.g. OCH 3 or OCH 2 CH 3 ).
- Rs may be halo (e.g. fluorine).
- the compounds of the first aspect of the invention are exemplified in the following structures:
- the compounds are:
- the invention in a second aspect relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.
- compositions according to the present invention may be suitable for the treatment or prevention of a proliferative disease. Accordingly, in another aspect the invention relates to a method of treating or preventing a proliferative disease in a subject, the method comprising administering to the subject an effective amount of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention.
- the present invention relates to the use of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention in the manufacture of a medicament for treating or preventing a proliferative disease.
- the present invention relates to the use of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention for the treatment or prevention of a proliferative disease in a subject.
- the present invention relates to a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention for use in the treatment or prevention of a proliferative disease in a subject.
- the proliferative disease is cancer, preferably a solid tumour.
- the cancer is selected from the group consisting of breast cancer, lung cancer, prostate cancer, ovarian cancer, uterine cancer brain cancer, skin cancer, colon cancer and bladder cancer.
- an 'effective amount' is an amount sufficient to produce a desired therapeutic or pharmacological effect in the subject being treated.
- the invention relates to a method of completely or partially preventing the recurrence of a solid tumour in a subject, the method comprising administering to the subject an effective amount of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention.
- the invention relates to the use of a compound according to the first aspect of the invention or the pharmaceutical composition according to the second aspect of the invention in the manufacture of a medicament for completely or partially preventing the recurrence of a solid tumour.
- the present invention relates to the use of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention for completely or partially preventing the recurrence of a solid tumour in a subject.
- the present invention relates to a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention for use in completely or partially preventing the recurrence of a solid tumour in a subject.
- Compounds and pharmaceutical compositions according to the present invention may be suitable for the treatment or prevention of an inflammatory disease or disorder. Accordingly, in another aspect the present invention relates to a method of treating an inflammatory disease or disorder in a subject, the method comprising administering to the subject an effective amount of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention. In a further aspect the present invention relates to the use of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention in the manufacture of a medicament for treating an inflammatory disease or disorder.
- the present invention relates to the use of a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention for the treatment of an inflammatory disease or disorder in a subject.
- the present invention relates to a compound of formula (I) according to the first aspect of the invention or a pharmaceutical composition according to the second aspect of the invention for use in the treatment of an inflammatory disease or disorder in a subject.
- the inflammatory disease or disorder may be osteoarthritis, inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), ulcerative proctitis, distal colitis, an autoimmune disorder (e.g. SLE, rheumatoid arthritis, glomerulonephritis), asthma or a disease involving pulmonary inflammation, or a cardiovascular disorder (e.g. atherosclerosis, hypertension and lipid dyscrasia).
- inflammatory bowel disease e.g. ulcerative colitis and Crohn's disease
- ulcerative proctitis e.g. SLE, rheumatoid arthritis, glomerulonephritis
- asthma or a disease involving pulmonary inflammation e.g. atherosclerosis, hypertension and lipid dyscrasia
- a cardiovascular disorder e.g. atherosclerosis, hypertension and lipid dyscrasia
- the compounds of formula (I) may be used in therapy alone or in combination with one or more other agents (e.g. chemotherapeutic or anti-inflammatory agents), for example, as part of a combination therapy.
- agents e.g. chemotherapeutic or anti-inflammatory agents
- the present invention relates to a process for preparing a compound of formula (I) comprising the steps of:
- the present invention relates to a process for preparing a compound of formula (I) comprising the steps of:
- the present invention relates to a process for preparing a compound of formula (I) comprising the steps of:
- Figure 1 Imaging and quantitation of actin filaments in SK-N-SH neuroblastoma cells treated with compound (A) 3504, (B) 3507 and (C) 3516. Cells were stained with 488-
- Atto-Phallodin and DAPI to visualize the actin filament bundles and the nucleus, respectively.
- Shown in the top panel is a representative grey scale immunofluorescent image from control (vehicle alone), 5 ⁇ and 10 ⁇ treated cells.
- the middle panel is a representative grey scale immunofluorescent image from control (vehicle alone), 5 ⁇ and 10 ⁇ treated cells.
- Figure 3 Impact of compound 3507 on Tpm3.1 -regulated actin-filament depolymerisation kinetics.
- a and B Depolymerisation time course of 6 ⁇ actin filaments (35 % pyrene labelled) diluted 12-fold into F-actin buffer (100 mM NaCI, 10 mM Tris-HCI pH 7.0, 2 mM MgCI 2 , 1 mM EGTA, 0.2 mM CaCI 2 , 0.2 mM ATP, 0.5 mM DTT, 0.01 % (v/v) NaN 3 ) in the presence or absence of saturating amounts (10 ⁇ ) of Tpm3.1 .
- F-actin buffer 100 mM NaCI, 10 mM Tris-HCI pH 7.0, 2 mM MgCI 2 , 1 mM EGTA, 0.2 mM CaCI 2 , 0.2 mM ATP, 0.5 mM DTT, 0.01 % (v/v) NaN 3
- Figure 4 Compound 3507/ 30%w/v Dexolve-7 was administered IP daily at 150 mg/kg for 18 days in a flank xenograft model of neuroblastoma (CHLA-20). Tumour volume was measured every 2-3 days.
- Figure 5 Compound 3507/ 30%w/v Dexolve-7 was administered IV 2x/week at 60 mg/kg for 14 days in a flank xenograft model of melanoma (A375). Tumour volume was measured every 2-3 days. ** p ⁇ 0.01 .
- the invention is based on the surprising finding that compounds of general formula (I) effectively inhibit tropomyosin, which results in unexpected improvement in the treatment of proliferative diseases, particularly cancer.
- the development of the actin cytoskeleton involves a number of ancillary control and regulatory proteins. Identification and specific targeting of actin regulatory proteins associated with the cytoskeleton of cancer cells offers the opportunity to develop cancer specific drugs without unwanted side effects.
- Actin filaments are constructed through the polymerisation of globular actin protein monomers.
- the actin monomer is polar, with one end bearing a positive charge and the other end a negative charge.
- the actin filaments thus have all the actin proteins aligned in one direction.
- These filaments have secondary coiled proteins, tropomyosins, associated with them.
- the tropomyosins play an integral role in regulating the function of actin filaments.
- the actin filaments are made up of polymeric actin monomers with tropomyosin dimers sitting in the alpha helical groove of the actin filament to form a homopolymer.
- tropomyosin isoforms there are more than 40 mammalian tropomyosin isoforms, each of which regulates specific actin filaments.
- tropomyosins that regulate the cytoskeleton of cancer cells; disruption of this interaction offers a basis to specifically treat cancer cells.
- Typical optional substituents include Ci-C 4 alkyl, C 2 -C 4 alkenyl, OH, halogen, O(Ci-C 4 alkyl), NR a R b wherein R a and R b are independently selected from H, C1-C3 alkyl, CONH 2 , SH, S(d-C 3 alkyl), -CH 2 -O(Ci -3 alkyl), C 6- io aryl, -CH 2 -phenyl, hydroxyl-(Ci-3 alkyl), and halo-(Ci-3 alkyl).
- Presently preferred optional substituents include d-3 alkyl, d-3 alkoxy, -CH 2 -(Ci-3)alkoxy, ⁇ - ⁇ aryl, -CH 2 -phenyl, halogen, OH, hydroxy-(Ci -3 )alkyl, and halo-(Ci -3 )alkyl, e.g, CF 3 , CH 2 CF 3 .
- acyl means an alkyl-CO- group in which the alkyl group is as described herein.
- examples of acyl include acetyl and benzoyl.
- the alkyl group may be a C1-C6 alkyl, Ci-C 4 alkyl, or C1-C3 alkyl group.
- the group may be a terminal group or a bridging group.
- Alkyl as a group or part of a group refers to a straight or branched aliphatic hydrocarbon group having 1 -12 carbon atoms, or 1 -10 carbon atoms, or 1 -6 carbon atoms, or 1 -4 carbon atoms, or 1 -3 carbon atoms.
- alkyl includes, but is not limited to, methyl, ethyl, 1 -propyl, isopropyl, 1 -butyl, 2-butyl, isobutyl, terf-butyl, amyl, 1 ,2-dimethylpropyl, 1 , 1 -dimethylpropyl, pentyl, isopentyl, hexyl, 4- methylpentyl, 1 -methylpentyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 3,3- dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 1 ,2,2-trimethylpropyl, 1 , 1 ,2- trimethylpropyl, 2-ethylpentyl, 3-ethylpentyl, heptyl, 1 -methylhexyl, 2,2-dimethylpentyl,
- the group may be a terminal group or a bridging group.
- Alkenyl as a group or part of a group denotes an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched such as a group having 2-12 carbon atoms, or 2-6 carbon atoms, or 2-4 carbon atoms, in the normal chain.
- the group may contain a plurality of double bonds in the normal chain and the orientation about each double bond is independently cis or trans, E or Z.
- alkenyl groups include, but are not limited to, ethenyl, vinyl, allyl, 1 -methylvinyl, 1 -propenyl, 2-propenyl, 2-methyl-1 -propenyl, 2-methyl-1 -propenyl, 1 -butenyl, 2-butenyl, 3-butentyl, 1 ,3-butadienyl, 1 -pentenyl, 2-pententyl, 3-pentenyl, 4-pentenyl, 1 ,3-pentadienyl, 2,4-pentadienyl, 1 ,4-pentadienyl, 3-methyl-2-butenyl, 1 -hexenyl, 2-hexenyl, 3-hexenyl, 1 ,3-hexadienyl, 1 ,4-hexadienyl, 2-methylpentenyl, 1 -heptenyl, 2-heptentyl, 3-heptenyl, 1 -
- the group may be a terminal group or a bridging group.
- Alkenyloxy refers to an -O- alkenyl group in which alkenyl is as defined herein. Preferred alkenyloxy groups are C2-C12 alkenyloxy groups.
- the group may be a terminal group or a bridging group.
- alkyloxy and alkoxy are synonymous and refer to an -O-alkyl group in which alkyl is defined herein.
- Presently preferred alkoxy groups are C1-6 alkoxy or Ci -4 alkoxy or d-3 alkoxy. Examples include, but are not limited to, methoxy,ethoxy, n-propoxy, isopropoxy, sec-butoxy, tert-butoxy, and the like.
- the group may be a terminal group or a bridging group.
- Alkylamino includes both mono-alkylamino and dialkylamino, unless specified.
- Mono- alkylamino means a -NH-alkyl group, in which alkyl is as defined above.
- Dialkylamino means a -N(alkyl) 2 group, in which each alkyl may be the same or different and are each as defined herein for alkyl.
- the alkyl group may be a C1 -C6 alkyl group.
- the group may be a terminal group or a bridging group.
- Alkynyl as a group or part of a group means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched and may have from 2-12 carbon atoms or 2-6 carbon atoms or 2-4 carbon atoms in the normal chain. Exemplary structures include, but are not limited to, ethynyl and propynyl.
- the group may be a terminal group or a bridging group.
- Alkynyloxy refers to an -O-alkynyl group in which alkynyl is as defined herein. Presently preferred alkynyloxy groups are C2-C6 alkynyloxy groups, C2-C 4 alkynyloxy.
- the group may be a terminal group or a bridging group.
- Aryl as a group or part of a group denotes (i) an optionally substituted monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) that may have from 5-18 atoms per ring.
- Presently preferred aryl groups have 6-14 atoms per ring, or more preferably 6-10 atoms per ring.
- aryl groups include phenyl, naphthyl, phenanthryl and the like; (ii) an optionally substituted partially saturated bicyclic aromatic carbocyclic moiety in which a phenyl and a C 5-7 cycloalkyl or C5 -7 cycloalkenyl group are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl or indanyl.
- the group may be a terminal group or a bridging group.
- Cycloalkenyl means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and may have from 5-10 carbon atoms per ring.
- Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.
- the cycloalkenyl group may be substituted by one or more substituent groups.
- the group may be a terminal group or a bridging group.
- Cycloalkyl refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle that may contain from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified. It includes monocyclic systems such as cyclopropyl and cyclohexyl, bicyclic systems such as decalin, and polycyclic systems such as adamantane. The group may be a terminal group or a bridging group.
- carrier ring refers to a carbon-based ring system. It is intended to include aryl, cycloalkenyl, cycloalkyl, and heteroaryl groups, as defined herein.
- halogen or halo are synonymous and refer to fluorine, chlorine, bromine or iodine.
- Heteroaryl either alone or as part of a group refers to groups containing an aromatic ring (such as a 5- or 6-membered aromatic ring) having one or more heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include nitrogen, oxygen and sulphur.
- heteroaryl examples include thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1 H-indazole, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isooxazole, furazane, phenoxazine, 2-,
- Certain compounds of the disclosed embodiments may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof, are intended to be within the scope of the subject matter described and claimed.
- formula (I) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds.
- formula (I) includes compounds having the indicated structure, including the hydrated or solvated form, as well as the non-hydrated and non-solvated forms.
- pharmaceutically acceptable salt refers to those salts which, within the scope of sound medical judgement, are suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1 -19.
- the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid.
- Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulphuric, and phosphoric acid.
- Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulphonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucoronic, fumaric, maleic, pyruvic, alkyl sulphonic, arylsulphonic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p- hydroxybenzoic, phenylacetic, mandelic, ambonic, pamoic, pantothenic, sulphanilic, cyclohexylaminosulphonic, stearic, algenic, ⁇ -hydroxybutyric, galactaric, and galacturonic acids.
- Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include metallic salts made from lithium, sodium, potassium, magnesium, calcium, aluminium, and zinc, and organic salts made from organic bases such as choline, diethanolamine, morpholine.
- inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
- Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of the present invention.
- metabolic means e.g. by hydrolysis, reduction or oxidation
- an ester prodrug of a compound of the present invention containing a hydroxyl group may be convertible by hydrolysis in vivo to the parent molecule.
- Suitable esters are for example, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- -hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.
- treating encompasses curing, ameliorating or tempering the severity of cancer or its associated symptoms.
- Preventing means preventing the occurrence of the cancer or tempering the severity of the cancer if it develops subsequent to the administration of the compounds or pharmaceutical compositions of the present invention. This prevents the onset of clinically evident unwanted cell proliferation altogether or the onset of a pre- clinically evident stage of unwanted rapid cell proliferation in individuals at risk. Also intended to be encompassed by this definition is the prevention of metastases of malignant cells or the arrest or reversal of the progression of malignant cells.
- terapéuticaally effective or “pharmacologically effective” are intended to qualify the amount of each agent which will achieve the goal of improvement in disease severity and the frequency of incidence over treatment of each agent by itself while avoiding adverse side effects typically associated with other therapies.
- a “pharmaceutical carrier, diluent or excipient” includes, but is not limited to, any physiological buffered (i.e., about pH 7.0 to 7.4) medium comprising a suitable water soluble organic carrier, conventional solvents, dispersion media, fillers, solid carriers, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents.
- suitable water soluble organic carriers include, but are not limited to saline, dextrose, corn oil, dimethylsulphoxide, and gelatine capsules.
- lactose lactose
- mannitol corn starch
- potato starch binders such as crystalline cellulose, cellulose derivatives, acacia, gelatines, disintegrators such as sodium carboxymethyl-cellulose, and lubricants such as talc or magnesium stearate.
- binders such as crystalline cellulose, cellulose derivatives, acacia, gelatines, disintegrators such as sodium carboxymethyl-cellulose, and lubricants such as talc or magnesium stearate.
- Subject includes any human or non-human animal.
- the compounds of the present invention may also be useful for veterinary treatment of mammals, including companion animals and farm animals, such as, but not limited to dogs, cats, horses, cows, sheep, and pigs.
- administering and variations of that term including “administer” and “administration”, includes contacting, applying, delivering or providing a compound or composition of the invention to an organism, or a surface by any appropriate means.
- the next step is N-alkylation of the substituted indole, as show in Scheme 5.
- the N-alkylation can be performed prior to ligation of the linking group.
- N-alkylated indole can be further ligated with a number of linking groups, specific conditions being used for N-linked compounds as shown in Scheme 6.
- Scheme 6 The methods described above in Schemes 4-6 may offer one or more advantages including high yields, control of stereochemistry, few synthetic steps and reaction conditions that are amenable to large scale manufacture.
- the compounds of general formula (I) according to the present invention, and pharmaceutical compositions thereof, may be used in the treatment or prevention of proliferative diseases, preferably cancer.
- the compounds and compositions of the invention may be useful for the treatment of a wide variety of cancers (tumours), including but not limited to, solid tumours, such as for example, breast cancer, lung cancer, prostate cancer, ovarian cancer, uterine cancer brain cancer, skin cancer, colon cancer and bladder cancer.
- cancers tumors
- compounds of the present invention may possess superior pharmaceutical properties, such as improved resistance to conjugation via glucuronyl transferases and other water solubilizing transferases such as sulphases, which may be over-expressed on proliferative cells such as cancer cells. This may advantageously confer superior pharmaceutical properties, such as an enhanced pharmacokinetic profile through reduced conjugation and elimination.
- compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
- the compounds or pharmaceutical compositions of the present invention may be administered orally, intravenously, intranasally, rectally, parenterally, subcutaneously, intramuscularly, topically or by any means which delivers an effective amount of the active agent to the tissue or site to be treated. It will be appreciated that different dosages may be required for treating different disorders.
- An effective amount of an agent is that amount which causes a statistically significant decrease in neoplastic cell count, growth, or size.
- Neoplastic disorders responsive to the agents of the present invention include, but are not limited to, breast cancer.
- the dosage form and amount of the compounds or pharmaceutical compositions of the present invention can be readily established by reference to known treatment or prophylactic regimens.
- the compounds and pharmaceutical compositions may be formulated for oral, injectable, rectal, parenteral, subcutaneous, intravenous or intramuscular delivery.
- suitable pharmaceutically acceptable excipients or carriers described above.
- one or more compounds may be combined with a sterile aqueous solution which is preferably isotonic with the blood of the recipient.
- a sterile aqueous solution which is preferably isotonic with the blood of the recipient.
- Such formulations may be prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride or glycine, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile.
- Suitable formulations may include cyclodextrins (e.g. sulfobutyl-ether- beta-cyclodextrin, or SBECD, commercially-available as Dexolve, or the formulation aid known as Captisol).
- the formulations may be present in unit or multi-dose containers such as sealed ampoules or vials.
- the amount of therapeutically effective compound that is administered and the dosage regimen for treating a disease condition with the compounds and/or pharmaceutical compositions of the invention depends on a variety of factors, including the age, weight, sex, and medical condition of the subject, the severity of the disease, the route and frequency of administration, the particular compound employed, the location of the unwanted proliferating cells, as well as the pharmacokinetic properties of the individual treated, and thus may vary widely.
- the dosage will generally be lower if the compounds are administered locally rather than system ically, and for prevention rather than for treatment. Such treatments may be administered as often as necessary and for the period of time judged necessary by the treating physician.
- the dosage regime or therapeutically effective amount of the inhibitor to be administrated may need to be optimized for each individual.
- the pharmaceutical compositions may contain active ingredient in the range of about 0.1 to 2000 mg, preferably in the range of about 0.5 to 500 mg and most preferably between about 1 and 200 mg.
- the daily dose can be administered in one to four doses per day.
- the compounds of the present invention may be administered along with a pharmaceutical carrier, diluent or excipient as described above.
- the compounds may be administered in combination with other agents, for example, chemotherapeutic or immune-stimulating drugs or therapeutic agents.
- ком ⁇ онент therapy in defining use of a compound of the present invention and one or more other pharmaceutical agents, are intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single formulation having a fixed ratio of these active agents, or in multiple, separate formulations of each agent.
- one or more compounds of general formula (I) may be formulated or administered in combination with one or more other therapeutic agents.
- one or more compounds of general formula (I) may be included in combination treatment regimens with surgery and/or other known treatments or therapeutic agents, such as other anticancer agents, in particular, chemotherapeutic agents, radiotherapeutic agents, and/or adjuvant or prophylactic agents.
- antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which could be selected for treatment of cancers or other neoplasias by combination drug chemotherapy.
- anti-neoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous agents.
- other anti-neoplastic agents such as metallomatrix proteases inhibitors may be used.
- Suitable agents which may be used in combination therapy will be recognized by those of skill in the art. Suitable agents are listed, for example, in the Merck Index, An Encyclopaedia of Chemicals, Drugs and Biologicals, 12 th Ed., 1996, the entire contents of which are incorporated herein by reference.
- Combination regimens may involve the active agents being administered together, sequentially, or spaced apart as appropriate in each case.
- Combinations of active agents including compounds of the invention may be synergistic.
- the co-administration of compounds of the general formula (I) may be effected by a compound of the general formula (I) being in the same unit dose as a chemotherapeutic or other anti-cancer agent, or the compound of the general formula (I) and the chemotherapeutic or other anti-cancer agents may be present in individual and discrete unit doses administered at the same, or at a similar time.
- Sequential administration may be in any order as required, and may require an ongoing physiological effect of the first or initial compound to be current when the second or later compound is administered, especially where a cumulative or synergistic effect is desired.
- Tosyl hydrazine (5.36 g, 28.9 mmol) was added to a stirred solution of 2,3-dimethyl-1 H- indole-5-carbaldehyde (5.0 g, 28.9 mmol) in dry 1 ,4-dioxane (100 mL) at room temperature. The temperature was increased to 80 °C and maintained for 2 hours before cooling to 0 °C.
- Step 6-1 Preparation of (3-((2,3-dimethyl-1-(3-chloropropyl)-1H-indol-5- yl)methyl)phenyl)(4-(4-fluorophenethyl)piperazin-1 -yljmethanone
- Step 6-2 Preparation of Compound 3501, (3-((2,3-dimethyl-1-(3-(4-methylpiperazin-1- yl)propyl)-1H-indol-5-yl)methyl)phenyl)(4-(4-fluorophenethy ⁇
- reaction mixture was cooled to room temperature, diluted with ethyl acetate (60 mL), washed with water and brine solution, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to afford the crude product.
- Compound 3502 (3-((2,3-dimethyl-1 -(3-(4-methylpiperazin-1 -yl)propyl)-1 H-indol-5- yl)methyl)phenyl)(4-(4-methoxyphenethyl)piperazin-1 -yl)methanone (34%).
- BBr 3 (12.18 ml_, 128.40 mmol) was added to a stirred solution of 5-methoxy-2,3- dimethyl-1 /-/-indole in DCM (50 ml_) at 0 °C. The temperature was maintained at 0-5 °C for 2 hours. After complete consumption of the starting material, the reaction mixture was basified using with saturated NaHC0 3 then extracted with CH2CI2. The organic layer was washed with brine solution, dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure to afford the crude product.
- Step 3 Preparation of ieri-butyl 5-hydroxy-2,3-dimethyl-1 H-indole-1 -carboxylate
- Step 4 Preparation of tert-butyl 5-(3-(methoxycarbonyl)phenoxy)-2,3-dimethyl-1H- indole- 1 -carboxylate
- Step 6 Preparation of (3-((2,3-dimethyl-1H-indol-5-yl)oxy)phenyl)(4-(4- fluorophenethyljpiperazin- 1 -yljmethanone
- DIPEA 0.70 mL, 4.44 mmol
- HATU 0.50 g, 1 .33 mmol
- reaction mass was cooled to 0 °C, 1 -(4- fluorophenethyl)piperazine (0.32 g, 1 .33 mmol) was added and the reaction mixture was stirred at room temperature overnight. After complete consumption of the starting material, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to afford the crude product.
- the crude compound was purified on 100-200 mesh silica eluting with 30% ethyl acetate in petroleum ether to obtain (3-((2,3-dimethyl-1 /-/-indol-5-yl)oxy)phenyl)(4-(4- fluorophenethyl)piperazin-1 -yl)methanone as a yellow solid (410 mg, 97%).
- Step 7-1 Preparation of (3-((1-(3-chloropropyl)-2,3-dimethyl-1H-indol-5- yl)oxy)phenyl)(4-(4-fluorophenethyl)piperazin-1-yl)methanone
- KOiBu (0.29 g, 4.434 mmol) was added portionwise to a stirred solution of (3-((2,3- dimethyl-1 - -indol-5-yl)oxy)phenyl)(4-(4-fluorophenethyl)piperazin-1 -yl)methanone (0.41 g, 0.88 mmol) in DMF (5 mL) at 0 °C. The mixture was allowed to warm to room temperature for 30 minutes. To this, bromochloropropane (0.43 mL, 4.43 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to room temperature and was stirred for 3 hours.
- Step 7-2 Preparation of Compound 3507, (3-((2,3-dimethyl-1-(3-(4-methylpiperazin-1- yljpropyl)- 1H-indol-5-yl)oxy)phenyl)(4-(4-fluorophenethyl)piperazin- 1 -yljmethanone
- reaction mixture was cooled to room temperature, diluted with ethyl acetate (30 mL), washed with water and brine, dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure to afford the crude product.
- Compound 3508 (3-((2,3-dimethyl-1 -(3-(4-methylpiperazin-1 -yl)propyl)-1 H-indol-5- yl)oxy)phenyl)(4-(4-methoxyphenethyl)piperazin-1 -yl)methanone (6%).
- Step 1 Preparation of (3-nitrophenyl)(4-phenethylpiperazin-1 -yl)methanone
- Step 5 Preparation of Compound 3513, (3-((2,3-dimethyl-1 -(3-(4-methylpiperazin-1 - yljpropyl) - 1 H-indol-5-yl)amino)phenyl) (4-(4-fluorophenethyl)piperazin- 1 -yljmethanone
- Step 1 and 2 Preparation of methyl 4-((2,3-dimethyl-1H-indol-5-yl)methyl)benzoate
- Step 4 Preparation of (4-((2,3-dimethyl-1H-indol-5-yl)methyl)phenyl)(4- phenethylpiperazin- 1 -yljmethanone
- Step 5-1 Preparation of (4-((1-(3-chloropropyl)-2,3-dimethyl-1H-indol-5- yljmethyljphenyl) (4-phenethylpiperazin- 1 -yljmethanone
- Step 5-2 Preparation of Compound 3524, (4-((2,3-dimethyl-1 -(3-(4-methylpiperazin-1 - yl)propyl)-1H-indol-5-yl)methyl)phenyl)(4-phenethylpipe
- Step 1 Preparation of tert-butyl 5-(4-(methoxycarbonyl)phenoxy)-2,3-dimethyl-1H- indole- 1 -carboxylate
- Step 4-1 Preparation of (4-((1-(3-chloropropyl)-2,3-dimethyl-1H-indol-5- yl)oxy)phenyl)(4-(4-fluorophenethyl)piperazin- 1 -yljmethanone
- Step 4-2 Preparation of Compound 3525, (4-((2,3-dimethyl-1-(3-(4-methylpiperazin-1- yl)propyl)-1H-indol-5-yl)oxy)phenyl)(4-(4-fluorophenethyl)pipe
- Step 3 Preparation of Compound 3531, (4-((2,3-dimethyl-1-(3-(4-methylpiperazin-1- yljpropyl) - 1 H-indol-5-yl)amino)phenyl) (4-(4-fluorophenethyl)piperazin- 1 -yljmethanone
- Step 1 Preparation of 2-(6-methoxynaphthalen-2-yl)ethan-1 -ol
- reaction mixture was quenched with ethyl acetate (3 mL) and saturated ammonium chloride solution (20 mL) at 0 °C, filtered and concentrated to give 2-(6-methoxynaphthalen-2-yl)ethan-1 -ol as a white solid (2.5 g, 95%).
- the crude compound was purified by flash column chromatography using 10-15% Ethyl acetate in petroleum ether as an eluent, to give 2-(2-bromoethyl)naphthalene as a yellow liquid (5.2 g, 71 %).
- Step 5 Preparation of (3-((2,3-dimethyl-1H-indol-5-yl)methyl)phenyl)(4-(2-(naphthalen- 2-yl)ethyl)piperazin- 1 -yljmethanone
- HATU (5 1 .0 mg, 1 .344 mmol) was added to a stirred solution of 3-((2,3-dimethyl-1 H- indol-5-yl)methyl)benzoic acid (250 mg, 0.896 mmol) and DIPEA (0.5 ml_) in DMF (5 ml_) at 0 °C.
- the reaction mixture was stirred for 30 minutes at room temperature.
- 1 -(2-(naphthalen-2-yl)ethyl)piperazine hydrochloride (273 mg, 0.986 mmol) was added and the mixture was stirred at room temperature overnight. The progress of the reaction was monitored by TLC. After complete consumption of the starting material, the reaction mixture was poured into ice water.
- Step 6-1 Preparation of (3-((1-(3-chloropropyl)-2,3-dimethyl-1H-indol-5- yl)methyl)phenyl)(4-(2-(6-methoxynaphthalen-2-yl)ethy ⁇ NaH (102 mg, 2.56 mmol) was added portionwise to a stirred solution of (3-((2,3- dimethyl-1 - -indol-5-yl)methyl)phenyl)(4-(2-(6-methoxynaphthalen-2-yl)ethyl)piperazin- 1 -yl)methanone (680 mg, 1 .22 mmol) in DMF (7 ml_) at 0 °C.
- Step 6-2 Preparation of Compound 3537, (3-((2,3-dimethyl-1-(3-(4-methylpiperazin-1- yljpropyl) - 1 H-indol-5-yl)methyl)phenyl) (4-(2-(naphthalen-2-yl)ethyl)piperazin- 1 - yljmethanone
- reaction mixture was cooled to room temperature and diluted with ethyl acetate (40 ml_). The mixture was washed with water and brine solution, dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure.
- HATU (680 mg, 1.79 mmol) was added to a stirred solution of 4-((2,3-dimethyl-1 H-indol- 5-yl)methyl)benzoic acid (250 mg, 0.896 mmol), DIPEA (0.45 mL, 2.68 mmol) in DMF (5 mL) at 0 °C.1-(2-(Naphthalen-2-yl)ethyl)piperazine hydrochloride (276 mg, 0.997 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. After complete consumption of the starting material, the reaction mixture was poured into ice water and extracted using ethyl acetate.
- Step 2-1 Preparation of (4-((1-(3-chloropropyl)-2,3-dimethyl-1H-indol-5- yl)methyl)phenyl)(4-(2-(naphthalen-2-yl)ethyl)piperazin ⁇
- Step 6-2 Preparation of Compound 3542, (4-((2,3-dimethyl-1 -(3-(4-methylpiperazin-1 - yljpropyl) - 1 H-indol-5-yl)methyl)phenyl) (4-(2-(naphthalen-2-yl)ethyl)piperazin- 1 - yljmethanone
- To a stirred solution of (4-((1 -(3-chloropropyl)-2,3-dimethyl-1 H-indol-5- yl)methyl)phenyl)(4-(2-(naphthalen-2-yl)ethyl)piperazin-1 -yl)methanone (170 mg, 0.284 mmol) in acetonitrile (5 ml_) were added sodium iodide (88.09 mg, 0.58 mmol) and sodium carbonate (155 mg, 1 .47 mmol), followed by A/-methylpiperazine (1 17
- reaction mixture was heated to 75 °C for 16 hours. After complete consumption of the starting material, the reaction mixture was cooled to room temperature, diluted with ethyl acetate (40 ml_) and washed with water, followed by brine solution. The organic layer was dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure to afford the crude product.
- Step 4 Preparation of tert-butyl 4-(2-(quinolin-6-yl)ethyl)piperazine-1-carboxylate
- Step 6-1 Preparation of methyl 4-((1-(3-chloropropyl)-2,3-dimethyl-1H-indol-5- yljmethyljbenzoate NaH (400 mg, 16.7 mmol) was added portionwise to a stirred solution of methyl 4-((2,3- dimethyl-1 H-indol-5-yl)methyl)benzoate (830 mg, 2.8 mmol) in DMF (10 ml_) at 0 °C. The mixture was allowed to warm to room temperature for 30 minutes.
- Step 6-2 Preparation of methyl 4-((2,3-dimethyl-1-(3-(4-methylpiperazin-1-yl)propyl)- 1 H-indol-5-yl)methyl)benzoate
- methyl 4-((1 -(3-chloropropyl)-2,3-dimethyl-1 H-indol-5- yl)methyl)benzoate (380 mg, 1.0 mmol) in acetonitrile (12 ml_) at room temperature, sodium iodide (380 mg, 2.5 mmol) and sodium carbonate (270 mg, 2.5 mmol) were added, followed by A/-methylpiperazine (250 mg, 2.5 mmol).
- the reaction mixture was heated to 80 °C for 12 hours. After complete consumption of the starting material, the reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with water and brine solution, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to afford the crude product.
- the crude compound was purified by flash column chromatography to afford methyl 4-((2,3-dimethyl-1 -(3-(4-methylpiperazin- 1 -yl)propyl)-1 H-indol-5-yl)methyl)benzoate (310 mg, 67%).
- Step 7 Preparation of 4-((2,3-dimethyl-1-(3-(4-methylpiperazin-1-yl)propyl)-1H-indol-5- yl)methyl)benzoic acid
- Step 8 Preparation of Compound 3541, (3-((2,3-dimethyl-1-(3-(4-methylpiperazin-1- yljpropyl)- 1H-indol-5-yl)methyl)phenyl)(4-(2-(quinolin-6-yl)ethyl)piperazin-1 ⁇
- each cell line was then exposed to increasing concentrations of each respective analogue (0.03, 0.3, 3 and 30 ⁇ for compounds in Table 1 ; 0.1 , 0.3, 1 , 3, 10 and 30 ⁇ for compounds in Table 2), cultured for a further 72 hours and exposed to cell-titre luminescent reagent (100 L/well) for a further 30 min) to assess for cell viability.
- Luminescence was captured using an EnVision multilabel reader and the data for each analogue concentration was normalised, as a percentage, to the no treatment control.
- semi-log plots of Percent of Control versus concentration were prepared and IC50 determined using linear regression analysis.
- the anti-proliferative activity of compound 3507 was further evaluated in cell lines representative of melanoma, prostate cancer, leukaemia and neuroblastoma. Cell viability after 72 hours exposure to increasing concentrations of compound 3507 was measured using an MTS viability assay. Cell viability was normalized to control (vehicle alone) and dose-response curves, and relative inhibitory concentration (IC50) values were determined using GraphPad Prism 6. Table 3. Anti-proliferative activity of compound 3507 against a range of somatic cancer cells.
- SK-N-SH neuroblastoma cells were seeded at 1800 cells/well in a 384 Perkin Elmer High Content Imaging "View" plate and left to plate down 24 hours prior to treatment. Cells were then treated with 0-40 ⁇ of the test compounds (1 :2 serial dilution in a 10 point dose response).
- any compound, which interacts with, and impacts Tpm3.1 function would nullify the protective effect of Tpm3.1 on actin depolymerisation.
- the depolymerisation of F-actin alone and F-actin-coated with the human homologue of Tpm3.1 was used as a comparative control. Briefly, Tpm3.1 was pre- incubated with F-actin for 20 minutes prior to diluting the filaments, to allow for proper assembly of the Tpm3.1 polymer.
- the initial rate (V 0 ) of F-actin depolymerisation was significantly slower for Tpm3.1 -containing actin filaments ( Figure 3A and C, p ⁇ 0.0001 ).
- Tpm3.1 The depolymerisation of F-actin alone and F-actin-coated with Tpm3.1 was then measured in the presence of test compound and initial rates of depolymerisation were compared.
- Tpm3.1 was pre-incubated with 50 ⁇ 3507 prior to being added to the actin filaments as previously described. In the presence of compound 3507 the ability of Tpm3.1 to polymerize and protect actin was impaired and the rate of depolymerisation was not significantly different to F-actin ( Figure 3B and D).
- PBMCs peripheral blood mononuclear cells
- PBMCs were treated with 50 ng/mL of phorbol 12-myristate 13-acetate (PMA) and 1 pg/mL of ionomycin and to stimulate the release of TNF-a and IL-6, PBMCs were treated with 100 ng/mL of lipopolysaccharide (LPS) from gram-negative bacteria. The PBMCs were then incubated at 37 °C and 5% CO2 for a further 6 hours and the cell supernatant was collected and a Homogenous Time Resolved Fluorescence (HTRF) assay was carried out following the manufacturer's instructions.
- PMA phorbol 12-myristate 13-acetate
- LPS lipopolysaccharide
- Cytokine release from the PBMCs was captured using a Perkin Elmer ENVISION 2104 microplate reader set at 615 nm and 665 nm respectively. Analysis of cytotoxicity under similar conditions using 100,000 PBMCs in a 96-well plate dosed with the same test compounds, with or without PMA and ionomycin stimulation at the 2 hour time point, revealed that any minor cell loss that had occurred, was insufficient to account for the inhibition of cytokine release observed in each of the six experiments.
- Group 1 received vehicle (30% w/v Dexolve-7 in sterile water) twice a week intravenously, and Group 2 was dosed with 3507/Dexolve-7 at 60 mg/kg, twice a week intravenously.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017104856A RU2017104856A (en) | 2014-07-16 | 2015-07-16 | FUNCTIONALIZED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS |
BR112017000714-2A BR112017000714A2 (en) | 2014-07-16 | 2015-07-16 | functionalized and substituted indols as anti-cancer agents |
AU2015227454A AU2015227454B2 (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
MX2017000613A MX2017000613A (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents. |
KR1020167035249A KR20170031097A (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
SG11201610195UA SG11201610195UA (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
US15/323,694 US20170152226A1 (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
JP2017502894A JP2017520612A (en) | 2014-07-16 | 2015-07-16 | Functionalized substituted indoles as anticancer agents |
CN201580038838.2A CN106661005A (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
CA2952557A CA2952557A1 (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
EP15822783.5A EP3169683A4 (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
PH12016502607A PH12016502607A1 (en) | 2014-07-16 | 2016-12-23 | Functionalised and substituted indoles as anti-cancer agents |
CONC2017/0000065A CO2017000065A2 (en) | 2014-07-16 | 2017-01-04 | Functionalized and substituted indoles as anti-cancer agents |
IL250074A IL250074A0 (en) | 2014-07-16 | 2017-01-11 | Functionalised and substituted indoles as anti-cancer agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462025207P | 2014-07-16 | 2014-07-16 | |
US62/025,207 | 2014-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016008011A1 true WO2016008011A1 (en) | 2016-01-21 |
Family
ID=55077744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2015/050400 WO2016008011A1 (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170152226A1 (en) |
EP (1) | EP3169683A4 (en) |
JP (1) | JP2017520612A (en) |
KR (1) | KR20170031097A (en) |
CN (1) | CN106661005A (en) |
AU (3) | AU2015227454B2 (en) |
BR (1) | BR112017000714A2 (en) |
CA (1) | CA2952557A1 (en) |
CL (1) | CL2017000054A1 (en) |
CO (1) | CO2017000065A2 (en) |
IL (1) | IL250074A0 (en) |
MX (1) | MX2017000613A (en) |
PH (1) | PH12016502607A1 (en) |
RU (1) | RU2017104856A (en) |
SG (1) | SG11201610195UA (en) |
WO (1) | WO2016008011A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3074378A1 (en) * | 2013-11-25 | 2016-10-05 | Novogen Ltd. | Functionalised and substituted indoles as anti-cancer agents |
KR101862765B1 (en) | 2017-04-21 | 2018-05-30 | 한국화학연구원 | N-Arylcyclicamine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases containing the same as an active ingredient |
US10328053B2 (en) | 2016-08-26 | 2019-06-25 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
CN110128415A (en) * | 2019-05-31 | 2019-08-16 | 沈阳药科大学 | Indoline-like compound as immunomodulator and preparation method thereof |
WO2019192506A1 (en) * | 2018-04-03 | 2019-10-10 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US11247987B2 (en) | 2017-10-06 | 2022-02-15 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
US11535618B2 (en) | 2018-10-05 | 2022-12-27 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
WO2023049953A1 (en) * | 2021-09-30 | 2023-04-06 | TroBio Therapeutics Pty Ltd | Substituted indole compounds and the use thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN110229091B (en) * | 2019-06-21 | 2022-11-22 | 天津科技大学 | 1, 5-disubstituted indole derivatives with leukotriene A4 hydrolase inhibition effect and application thereof |
CN113121429B (en) * | 2020-01-15 | 2024-04-26 | 鲁南制药集团股份有限公司 | C-Met kinase inhibitor and preparation method and application thereof |
CN113149897B (en) * | 2021-03-24 | 2023-10-31 | 福建省中科生物股份有限公司 | 2, 6-substituted-4-oxyterpene phenolic pyridine compound and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083653A1 (en) * | 2001-04-11 | 2002-10-24 | Amgen Inc. | Triazinyl acrylamide derivatives as kinase inhibitors |
WO2003015769A1 (en) * | 2001-08-17 | 2003-02-27 | Aventis Pharma Deutschland Gmbh | Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
US20040116388A1 (en) * | 1999-10-07 | 2004-06-17 | Amgen Inc. | Kinase inhibitors |
WO2004072025A2 (en) * | 2003-02-14 | 2004-08-26 | Aventis Pharma Deutschland Gmbh | Substituted n-arylheterocycles, method for production and use thereof as medicaments |
WO2011046954A1 (en) * | 2009-10-13 | 2011-04-21 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
WO2015074123A1 (en) * | 2013-11-25 | 2015-05-28 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024440A1 (en) * | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
MX2009006077A (en) * | 2007-01-08 | 2009-06-17 | Suven Life Sciences Ltd | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands. |
US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
-
2015
- 2015-07-16 EP EP15822783.5A patent/EP3169683A4/en not_active Withdrawn
- 2015-07-16 MX MX2017000613A patent/MX2017000613A/en unknown
- 2015-07-16 CA CA2952557A patent/CA2952557A1/en not_active Abandoned
- 2015-07-16 RU RU2017104856A patent/RU2017104856A/en unknown
- 2015-07-16 JP JP2017502894A patent/JP2017520612A/en active Pending
- 2015-07-16 WO PCT/AU2015/050400 patent/WO2016008011A1/en active Application Filing
- 2015-07-16 US US15/323,694 patent/US20170152226A1/en not_active Abandoned
- 2015-07-16 CN CN201580038838.2A patent/CN106661005A/en active Pending
- 2015-07-16 BR BR112017000714-2A patent/BR112017000714A2/en not_active Application Discontinuation
- 2015-07-16 KR KR1020167035249A patent/KR20170031097A/en unknown
- 2015-07-16 AU AU2015227454A patent/AU2015227454B2/en not_active Ceased
- 2015-07-16 SG SG11201610195UA patent/SG11201610195UA/en unknown
-
2016
- 2016-01-29 AU AU2016200541A patent/AU2016200541A1/en not_active Abandoned
- 2016-12-23 PH PH12016502607A patent/PH12016502607A1/en unknown
-
2017
- 2017-01-04 CO CONC2017/0000065A patent/CO2017000065A2/en unknown
- 2017-01-09 CL CL2017000054A patent/CL2017000054A1/en unknown
- 2017-01-11 IL IL250074A patent/IL250074A0/en unknown
- 2017-11-01 AU AU2017254894A patent/AU2017254894A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116388A1 (en) * | 1999-10-07 | 2004-06-17 | Amgen Inc. | Kinase inhibitors |
WO2002083653A1 (en) * | 2001-04-11 | 2002-10-24 | Amgen Inc. | Triazinyl acrylamide derivatives as kinase inhibitors |
WO2003015769A1 (en) * | 2001-08-17 | 2003-02-27 | Aventis Pharma Deutschland Gmbh | Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
WO2004072025A2 (en) * | 2003-02-14 | 2004-08-26 | Aventis Pharma Deutschland Gmbh | Substituted n-arylheterocycles, method for production and use thereof as medicaments |
WO2011046954A1 (en) * | 2009-10-13 | 2011-04-21 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
WO2015074123A1 (en) * | 2013-11-25 | 2015-05-28 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
Non-Patent Citations (4)
Title |
---|
DATABASE REGISTRY 12 April 2011 (2011-04-12), "1-(3- Methoxyphenyl)-5-methyl-N-[ 1-[2-(4-morpholinyl)ethyl]-1 H-indol-5-yl]-1H-1,2,3- triazole-4-carboxamide", XP055387326, retrieved from STN Database accession no. 1278979-52-4 * |
DATABASE REGISTRY 18 August 2011 (2011-08-18), "1- 4-(3- Methylphenyl)-N-[1-[2-(4-morpholinyl)ethyl]-1H-indol-5-yl]-piperazinecarboxamide", XP055387319, retrieved from STN Database accession no. 1319263-20-1 * |
DATABASE REGISTRY 4 April 2002 (2002-04-04), "N-[5-[[4- (Dimethylamino)phenyl]thio]-1,3,4-thiadiazol-2-yl]-2,3-dimethyl-1-(phenylmethyl)-1H- indole-5-carboxamide", XP055387329, retrieved from STN Database accession no. 403999-05-3 * |
See also references of EP3169683A4 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3074378A1 (en) * | 2013-11-25 | 2016-10-05 | Novogen Ltd. | Functionalised and substituted indoles as anti-cancer agents |
EP3074378A4 (en) * | 2013-11-25 | 2017-05-10 | Novogen Ltd. | Functionalised and substituted indoles as anti-cancer agents |
US10328053B2 (en) | 2016-08-26 | 2019-06-25 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10874640B2 (en) | 2016-08-26 | 2020-12-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
KR101862765B1 (en) | 2017-04-21 | 2018-05-30 | 한국화학연구원 | N-Arylcyclicamine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases containing the same as an active ingredient |
US11247987B2 (en) | 2017-10-06 | 2022-02-15 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US11420974B2 (en) | 2018-02-26 | 2022-08-23 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2019192506A1 (en) * | 2018-04-03 | 2019-10-10 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
US11535618B2 (en) | 2018-10-05 | 2022-12-27 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
US11814386B2 (en) | 2018-10-05 | 2023-11-14 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
CN110128415A (en) * | 2019-05-31 | 2019-08-16 | 沈阳药科大学 | Indoline-like compound as immunomodulator and preparation method thereof |
CN110128415B (en) * | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | Indoline compound used as immunomodulator and preparation method thereof |
WO2023049953A1 (en) * | 2021-09-30 | 2023-04-06 | TroBio Therapeutics Pty Ltd | Substituted indole compounds and the use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2017254894A1 (en) | 2017-11-23 |
MX2017000613A (en) | 2017-04-27 |
CA2952557A1 (en) | 2016-01-21 |
RU2017104856A (en) | 2018-08-16 |
SG11201610195UA (en) | 2017-01-27 |
CO2017000065A2 (en) | 2017-05-19 |
EP3169683A4 (en) | 2017-11-22 |
AU2016200541A1 (en) | 2016-02-18 |
PH12016502607A1 (en) | 2017-04-24 |
JP2017520612A (en) | 2017-07-27 |
US20170152226A1 (en) | 2017-06-01 |
AU2015227454B2 (en) | 2016-02-25 |
IL250074A0 (en) | 2017-03-30 |
CN106661005A (en) | 2017-05-10 |
BR112017000714A2 (en) | 2018-01-09 |
AU2015227454A1 (en) | 2016-02-04 |
KR20170031097A (en) | 2017-03-20 |
EP3169683A1 (en) | 2017-05-24 |
CL2017000054A1 (en) | 2017-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016008011A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
US20170166555A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
WO2016008010A1 (en) | Functionalised and substituted carbazoles as anti-cancer agents | |
TW200307535A (en) | Therapeutic agent for cancer | |
WO2016208592A1 (en) | Bicyclic heterocyclic amide derivative | |
JP7181565B2 (en) | A compound that inhibits YAP-TEAD binding, and a pharmaceutical composition for preventing or treating cancer containing the compound as an active ingredient | |
JP2019523230A (en) | Anti-metastatic 2H-selenopheno [3,2-h] chromene, their synthesis, and methods of using the same | |
JP6666458B2 (en) | Substituted amino 6-membered nitrogen-containing heterocyclic compounds and their production and use | |
US20170157135A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
JP6239103B2 (en) | Substance having tyrosine kinase inhibitory activity and preparation method and use thereof | |
AU2020424661B2 (en) | Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient | |
WO2014086102A1 (en) | Indole full ketone derivative used as tyrosine-kinase inhibitor | |
JP7184302B2 (en) | Compounds Useful for Inhibiting Human Trefoil Factor 3 | |
KR102421065B1 (en) | Method for preparing novel quinone-indolizine hybrid derivatives and anticancer composition containing the same | |
JPWO2017183723A1 (en) | KCNQ2-5 channel activator | |
KR101209702B1 (en) | Novel hydroxamic acid derivatives or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for the prevention or treatment of proliferative diseases containing the same as an active ingredient | |
JP2016216446A (en) | Polymorphic form of pyrrolidine-2,5-dione derivative, pharmaceutical composition and method of use as ido1 inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2015227454 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15822783 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2952557 Country of ref document: CA Ref document number: 20167035249 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015822783 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015822783 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12016502607 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15323694 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2017/0000065 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 250074 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2017502894 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/000613 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017000714 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017104856 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017000714 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170112 |